June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Optical coherence tomography angiography of type 3 macular neovascularization, a clinicopathologic correlation
Author Affiliations & Notes
  • Andreas Berlin
    Ophthalmology and Visual Sciences, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
    Ophthalmology, Universitatsklinikum Wurzburg, Wurzburg, Bayern, Germany
  • Diogo Cabral
    Ophthalmology, CEDOC - NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
  • Ling Chen
    Ophthalmology and Visual Sciences, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
    Chongqing Key Laboratory of Ophthalmology, and Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Sichuan, China
  • Jeffrey D Messinger
    Ophthalmology and Visual Sciences, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
  • Chandrakumar Balaratnasingam
    Ophthalmology and Visual Science, University of Western Australia Centre for Ophthalmology and Visual Science, Perth, Western Australia, Australia
    Lions Eye Institute, Nedlands, Western Australia, Australia
  • Randev Mendis
    Canberra Retina Center, Canberra, Western Australia, Austria
  • Daniela Ferrara
    Genentech Inc, South San Francisco, California, United States
  • K Bailey Freund
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
    Ophthalmology, New York University Grossman School of Medicine, New York, New York, United States
  • Christine A Curcio
    Ophthalmology and Visual Sciences, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
  • Footnotes
    Commercial Relationships   Andreas Berlin None; Diogo Cabral None; Ling Chen None; Jeffrey Messinger None; Chandrakumar Balaratnasingam None; Randev Mendis None; Daniela Ferrara Genentech, Inc, Code E (Employment), Roche, Code I (Personal Financial Interest); K Bailey Freund Genentech, Code C (Consultant/Contractor), Zeiss, Code C (Consultant/Contractor), Heidelberg Engineering, Code C (Consultant/Contractor), Allergan, Code C (Consultant/Contractor), Bayer, Code C (Consultant/Contractor), Novartis, Code C (Consultant/Contractor); Christine Curcio Genentech, Code F (Financial Support), Regeneron, Code F (Financial Support), Eye Sight Foundation Alabama, Code F (Financial Support), Macula Foundation, Code F (Financial Support), Research to Prevent Blindness, Code F (Financial Support), Macregen, Code I (Personal Financial Interest)
  • Footnotes
    Support  grant from the Dr. Werner Jackstädt-foundation
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1018 – F0265. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andreas Berlin, Diogo Cabral, Ling Chen, Jeffrey D Messinger, Chandrakumar Balaratnasingam, Randev Mendis, Daniela Ferrara, K Bailey Freund, Christine A Curcio; Optical coherence tomography angiography of type 3 macular neovascularization, a clinicopathologic correlation. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1018 – F0265.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Correlation of in vivo optical coherence tomography angiography (OCTA) of type 3 macular neovascularization (t3 MNV) secondary to AMD with corresponding ex vivo histology.
Exploring the overall value of clinical OCTA for disease observation, diagnosis, and staging by validating OCTA in the analysis of type 3 macular neovascularization secondary to AMD.

Methods : A white woman receiving anti-VEGF (OD, n=37; OS, n=6; last visits 3 and 2 months, respectively, before death at age 97 years) was monitored by optical coherence tomography (OCT) and angiography (OCT and dye-based). Eyes were recovered 4:05 hours after death, processed for macula-wide epoxy-resin histology, and scanned under an oil objective for high-resolution microscopy. Infrared reflectance and eye-tracked spectral-domain OCT(A) clinical imaging were correlated with ex vivo and high-resolution histologic images. Projection artifact removal based on three-dimensional vessel-shape estimation (VSE-PAR) and a Gaussian blur filter for preservation of neovascular flow signal was used.

Results : Clinical OCT(A) imaging showed several neovascular lesions within the central macula of both eyes. Two index lesions of different phenotypes in the right eye displayed a drusenoid pigment epithelium detachment (PED), characteristic of t3 MNV. Projection artifact removal based on VSE-PAR and a Gaussian blur filter demonstrated robust preservation of neovascular flow signal. OCTA decorrelation signal in lesion # 1 corresponded in histology to a vertically oriented collagen-ensheathed vascular complex originating from the intermediate capillary plexus. Lesion # 2 corresponded to a horizontally oriented vascular loop originating from the deep capillary plexus. Both lesions contacted basal laminar deposits that remained after the retinal pigment epithelium (RPE) disappeared due to death in situ or anterior migration. The sub-RPE-basal laminar space (between RPE-basal lamina and inner collagenous layer of Bruch’s membrane) underlying these vascular abnormalities contained calcific nodules and glial processes. No connection between the choriocapillaris and this space was observed for either lesion.

Conclusions : OCTA decorrelation signal of type 3 neovascularization corresponded to two intraretinal neo-vessel phenotypes on histology.
VSE-PAR and Gaussian blur filter demonstrated their value for further use in OCTA decorrelation signal processing.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×